Cas no 23651-95-8 (Droxidopa (80%))
Droxidopa (80%) Chemical and Physical Properties
Names and Identifiers
-
- Droxidopa
- (-)-(2S,3R)-2-Amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid
- L-threo-Droxidopa
- (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid
- (2S,3R)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid
- (2S,3R)-3-(3,4-Dihydroxyphenyl)-2-amino-3-hydroxypropanoic acid
- 3-dihydroxy-betthreo-dl-tyrosin
- 3-dihydroxy-dl-tyrosinethreo-bet
- DL-DOPS
- DL-threo-Dihydroxyphenylserine
- DL-THREO-DOPS
- DL-threo-Droxidopa
- DOPS
- Droxidopa L-threo 3,4-Dihydroxyphenylserine
- L-DOPS
- L-threo-3,4-Dihydroxyphenylserine
- SM5688
- L-threo 3,4-Dihydroxyphenylserine
- Northera
- threo-Dopaserine
- L-Threodops
- DL-threo-3,4-Dihydroxyphenylserine
- SM 5688
- Droxidopa (L-DOPS)
- threo-beta,3-Dihydroxy-DL-tyrosine
- beta,3-Dihydroxy-DL-tyrosine threo-
- L-threo-dihydroxyphenylserine
- DL-threo-3-(3,4-Dihydroxyphenyl)serine
- Serine, 3-(3,4-dihydroxyphenyl)-
- Droxidopa (80%)
- 3,4 threo DOPS
- Q-201050
- L-threo-DOPS
- 1260173-94-1
- SR-01000883755-1
- DROXIDOPA (MART.)
- 23651-95-8
- DTXSID201017236
- Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-
- DROXIDOPA [JAN]
- DROXIDOPA [USAN]
- 3,4-threo-DOPS
- SM-5688
- Norethra
- EN300-9430063
- DTXSID6046422
- DROXIDOPA [VANDF]
- D01277
- threo DOPS
- J7A92W69L7
- DROXIDOPA [MI]
- THREO-3,4-DIHYDROXYPHENYLSERINE, L-
- DL-Tyrosine, beta,3-dihydroxy-, threo-
- 3916-18-5
- AKOS015889899
- NCGC00344531-04
- L-TYROSINE, .BETA.,3-DIHYDROXY-, (.BETA.R)-
- (-)-threo-3-(3,4-Dihydroxyphenyl)-L-serine
- UNII-J7A92W69L7
- MFCD00799030
- Droxidopa (L-threo-3-(3,4-Dihydroxyphenyl)serine)
- Droxidopa (JP17/USAN/INN)
- 24A0V01WKS
- threo-DOPS
- D90266
- DROXIDOPA [MART.]
- L-Tyrosine, beta,3-dihydroxy-, (beta-R)-
- (-)-(2S,3R)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-3-HYDROXYPROPANOIC ACID
- D-TYROSINE, .BETA.,3-DIHYDROXY-, (.BETA.S)-REL-
- DROXIDOPA [INN]
- UNII-24A0V01WKS
- CHEBI:31524
- Droxydopa
- DL-Tyrosine, .beta.,3-dihydroxy-, threo-
- DROXIDOPA [ORANGE BOOK]
- AB01566868_01
- 1-14-00-00685 (Beilstein Handbook Reference)
- Q907853
- L-Tyrosine, beta,3-dihydroxy-, threo-
- NS00045584
- threo-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic acid
- Droxidopa (L-DOPS,SM-5688)
- DB06262
- Northera (TN)
- AS-61328
- droxidopum
- DL-threo- beta -(3,4-Dihydroxyphenyl)serine
- Droxidopa [Latin]
- SR-01000883755
- A816824
- DL-threo-beta-(3,4-Dihydroxyphenyl)serine
- Droxidopa (Latin)
- 23651-95-8,1260173-94-1(HCl)
- BRN 2852792
- L-DOPS;DOPS;SM5688
- HY-13458
- Serine, 3-(3,4-dihydroxyphenyl)-, DL-threo-
- EINECS 223-480-5
- s3041
- 3,4-DIHYDROXYPHENYLSERINE-THREO, DL-
- QXWYKJLNLSIPIN-JGVFFNPUSA-N
- Droxidopa [USAN:INN:JAN]
- L-DOPS, >=98% (HPLC)
- SCHEMBL134299
- (betaR)-beta,3-dihydroxy-L-tyrosine
- (-)-(2S,3R)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic acid
- L-Tyrosine, beta,3-dihydroxy-, (betaR)-
- DL threo 3,4 Dihydroxyphenylserine
- Threo-dihydroxyphenylserine
- BDBM50103611
- 3,4-Dihydroxyphenylserine
- Dops (TN)
- L-dihydroxyphenylserine
- GTPL7391
- DTXCID4026422
- L-threo DOPS
- DROXIDOPA [WHO-DD]
- H-DL--(3,4-Dihydroxyphenyl)-DL-Ser-OH
- BCP06516
- CCG-222060
- C01CA27
- (2S,3R)-3,4-dihydroxy-phenylserine
- L-threo-3-(3,4-Dihydroxyphenyl)serine
- CHEMBL2103827
- D4235
- (2RS,3RS)-2-Amino-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic acid;DL-DOPS;DL-Droxidopa
- DA-75128
- SBI-0654105.0001
- DA-52703
- L-threo-(3,4-dihydroxyphenyl)serine hydrochloride
- BRD-K20372197-001-03-1
- Droxidopa (JP18/USAN/INN)
- BRD-K20372197-001-02-3
-
- MDL： MFCD00799030
- Inchi： 1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1
- InChI Key： QXWYKJLNLSIPIN-JGVFFNPUSA-N
- SMILES： O[C@H](C1C=CC(=C(C=1)O)O)[C@@H](C(=O)O)N
- BRN： 2852792
Computed Properties
- Exact Mass: 213.06400
- Monoisotopic Mass: 213.06372245g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 5
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 15
- Rotatable Bond Count: 3
- Complexity: 235
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 2
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 124
- XLogP3: -3.2
Experimental Properties
- Color/Form: Crystallized from ethanol and ether, white to light brown crystals or crystalline powder, odorless and tasteless
- Melting Point: 225°C(dec.)(lit.)
- Boiling Point: 549.8±50.0 °C at 760 mmHg
- Flash Point: 286.3±30.1 °C
- Solubility: DMSO: ≥3mg/mL
- PSA: 124.01000
- LogP: 0.24340
- Merck: 3457
- Specific Rotation: D20 -39° (c = 1 in 1N aq HCl); D20 -42.0° (c = 1 in 1N aq HCl)
- Vapor Pressure: No data available
Droxidopa (80%) Security Information
-
Symbol:
- Prompt：warning
- Signal Word：Warning
- Hazard Statement： H315-H319
- Warning Statement： P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Hazard Category Code： 36/37/38
- Safety Instruction： 26
- RTECS：VT9626010
-
Hazardous Material Identification：
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Droxidopa (80%) Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | GQ680-50mg |
Droxidopa (80%) |
23651-95-8 | 98.0%(LC&T) | 50mg |
￥1271.0 | 2022-05-30 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | D859194-100mg |
Droxidopa |
23651-95-8 | >98.0% | 100mg |
￥1,898.00 | 2022-01-11 | |
| TRC | D689960-5mg |
L-threo-Droxidopa |
23651-95-8 | 5mg |
$68.00 | 2023-05-18 | ||
| TRC | D689960-25mg |
L-threo-Droxidopa |
23651-95-8 | 25mg |
$148.00 | 2023-05-18 | ||
| TRC | D689960-50mg |
L-threo-Droxidopa |
23651-95-8 | 50mg |
$ 253.00 | 2023-09-07 | ||
| TRC | D689960-100mg |
L-threo-Droxidopa |
23651-95-8 | 100mg |
$436.00 | 2023-05-18 | ||
| TRC | D689960-250mg |
L-threo-Droxidopa |
23651-95-8 | 250mg |
$ 587.00 | 2023-09-07 | ||
| TRC | D689960-500mg |
L-threo-Droxidopa |
23651-95-8 | 500mg |
$ 908.00 | 2023-09-07 | ||
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci8342-50mg |
Droxidopa |
23651-95-8 | 98% | 50mg |
￥1446.00 | 2023-09-09 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T2547-10 mg |
Droxidopa |
23651-95-8 | 99.66% | 10mg |
￥1317.00 | 2022-04-26 |
Droxidopa (80%) Suppliers
Audited Supplier
Droxidopa (80%) Related Literature
-
Juliana F. Rocha,André F. Pina,Sérgio F. Sousa,Nuno M. F. S. A. Cerqueira Catal. Sci. Technol. 2019 9 4864
-
Arumugam Sudalai,Alexander Khenkin,Ronny Neumann Org. Biomol. Chem. 2015 13 4374
Additional information on Droxidopa (80%)
Droxidopa (80%) and its Applications in Modern Medicine
Droxidopa (CAS no. 23651-95-8) is a synthetic amino acid derivative that has garnered significant attention in the field of pharmaceuticals due to its unique biochemical properties and therapeutic applications. As a highly pure form (80%) of Droxidopa, this compound has become a cornerstone in the development of treatments for various medical conditions, particularly those related to peripheral neuropathy and cardiovascular diseases. The increasing interest in this compound is driven by its ability to serve as a precursor for norepinephrine, a crucial neurotransmitter that plays a vital role in maintaining blood pressure and improving peripheral circulation.
The pharmacological significance of Droxidopa stems from its conversion into norepinephrine via the enzyme dopamine β-hydroxylase. This enzymatic conversion is essential for patients suffering from symptomatic orthostatic hypotension, a condition characterized by a sudden drop in blood pressure upon standing. The latest research indicates that Droxidopa can effectively increase norepinephrine levels in the synaptic cleft, thereby mitigating the symptoms associated with orthostatic hypotension. This mechanism of action has made Droxidopa a promising candidate for treating conditions such as diabetic neuropathy, where impaired sympathetic nervous system function contributes to poor blood flow and pain.
In recent years, clinical trials have demonstrated the efficacy of Droxidopa in improving symptoms related to peripheral neuropathy. A study published in the Journal of Neurology highlighted that patients treated with Droxidopa experienced a significant reduction in pain scores and an improvement in walking distance compared to placebo groups. These findings have bolstered the credibility of Droxidopa as a therapeutic agent and have prompted further investigation into its potential applications in other neurological disorders. The high purity (80%) of the compound ensures minimal impurities, which enhances its safety profile and therapeutic efficacy.
The synthesis and purification of Droxidopa (CAS no. 23651-95-8) require stringent quality control measures to maintain its high efficacy. Advanced synthetic techniques have been developed to achieve the desired purity level, ensuring that the final product meets pharmaceutical standards. These techniques often involve multi-step organic synthesis followed by chromatographic purification methods, which are critical for removing any potential contaminants that could affect the compound's stability and bioavailability.
One of the most compelling aspects of Droxidopa is its potential in managing cardiovascular conditions. Research has shown that increased norepinephrine levels can lead to vasoconstriction, which helps in maintaining blood pressure levels. This property makes Droxidopa particularly useful in treating patients with decompensated heart failure or those undergoing dialysis, where blood pressure regulation is often challenging. The latest studies are exploring the long-term effects of Droxidopa on patients with chronic heart failure, aiming to determine if it can provide sustained benefits beyond acute treatment scenarios.
The growing body of evidence supporting the use of Droxidopa has also sparked interest in its potential applications beyond traditional medical settings. For instance, researchers are investigating its role in enhancing athletic performance by improving endurance and reducing fatigue. While these applications are still under exploration, they highlight the versatility of Droxidopa and its potential impact on various fields.
In conclusion, Droxidopa (CAS no. 23651-95-8) is a highly pure (80%) compound with significant therapeutic potential in modern medicine. Its ability to increase norepinephrine levels offers promising solutions for conditions ranging from peripheral neuropathy to cardiovascular diseases. As research continues to uncover new applications and benefits, Droxidopa is poised to play an increasingly important role in patient care and treatment strategies worldwide.
23651-95-8 (Droxidopa (80%)) Related Products
- 60-18-4(L-Tyrosine)
- 51-65-0(2-Amino-3-(4-fluorophenyl)propanoic acid)
- 56-69-9(5-Hydroxy Tryptophan)
- 59-92-7(L-DOPA)
- 63-91-2(L-Phenylalanine)
- 66-02-4(3,5-Diiodo-DL-tyrosine)
- 51-48-9(L-Thyroxine)
- 51-49-0(D-Thyroxine)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
